Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.
Chen Z, Zheng Y, Cao W, Zhang Y, Zhao Z, Wang G, Zhao J, Cai S, Shao X, Huang J, Ye W, Huang Y, Li W, Huang X, Wu H, Wang X, Yin Y.
Chen Z, et al. Among authors: huang x, huang j, huang y.
Cancer Med. 2019 Sep;8(12):5544-5553. doi: 10.1002/cam4.2460. Epub 2019 Aug 6.
Cancer Med. 2019.
PMID: 31385461
Free PMC article.